Vanguard Group
TTNP

Vanguard Group’s Titan Pharmaceuticals TTNP Stock Holding History

Vanguard Group’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,103
Closed -$33.8K – 4483
2023
Q4 		$33.8K Hold
4,103
– – ﹤0.01% 4402
2023
Q3 		$38.9K Hold
4,103
– – ﹤0.01% 4441
2023
Q2 		$53K Hold
4,103
– – ﹤0.01% 4450
2023
Q1 		$68.1K Hold
4,103
– – ﹤0.01% 4438
2022
Q4 		$64.3K Buy
4,103
+7
+0.2% +$132 ﹤0.01% 4424
2022
Q3 		$88K Buy
4,096
+351
+9% +$9.06K ﹤0.01% 4505
2022
Q2 		$42K Sell
3,745
-6,576
-64% -$82K ﹤0.01% 4596
2022
Q1 		$197K Hold
10,321
– – ﹤0.01% 4538
2021
Q4 		$210K Sell
10,321
-14
-0.1% -$422 ﹤0.01% 4553
2021
Q3 		$386K Buy
10,335
+119
+1% +$5.21K ﹤0.01% 4414
2021
Q2 		$531K Buy
10,216
+6,576
+181% +$329K ﹤0.01% 4263
2021
Q1 		$217K Buy
3,640
+805
+28% +$53.3K ﹤0.01% 4249
2020
Q4 		$186K Buy
2,835
+917
+48% +$72.5K ﹤0.01% 4094
2020
Q3 		$190K Hold
1,918
– – ﹤0.01% 3959
2020
Q2 		$352K Hold
1,918
– – ﹤0.01% 3843
2020
Q1 		$268K Buy
1,918
+1,715
+845% +$268K ﹤0.01% 3816
2019
Q4 		$24K Sell
203
-702
-78% -$84.6K ﹤0.01% 4081
2019
Q3 		$146K Sell
905
-65
-7% -$29.3K ﹤0.01% 3994
2019
Q2 		$746K Buy
970
+181
+23% +$165K ﹤0.01% 3749
2019
Q1 		$842K Buy
789
+183
+30% +$178K ﹤0.01% 3672
2018
Q4 		$487K Buy
606
+486
+405% +$545K ﹤0.01% 3739
2018
Q3 		$90K Buy
120
+13
+12% +$35.3K ﹤0.01% 4089
2018
Q2 		$418K Hold
107
– – ﹤0.01% 3852
2018
Q1 		$404K Buy
107
+3
+3% +$12.5K ﹤0.01% 3825
2017
Q4 		$494K Sell
104
-27
-21% -$168K ﹤0.01% 3751
2017
Q3 		$827K Sell
131
-54
-29% -$334K ﹤0.01% 3638
2017
Q2 		$1.26M Sell
185
-12
-6% -$112K ﹤0.01% 3522
2017
Q1 		$2.33M Buy
197
+5
+3% +$70.3K ﹤0.01% 3337
2016
Q4 		$2.77M Buy
192
+18
+10% +$303K ﹤0.01% 3250
2016
Q3 		$3.69M Buy
174
+16
+10% +$311K ﹤0.01% 3146
2016
Q2 		$3.11M Buy
158
+74
+88% +$1.58M ﹤0.01% 3198
2016
Q1 		$1.45M Buy
84
+75
+833% +$1M ﹤0.01% 3486
2015
Q4 		$149K Buy
+9
New +$147K ﹤0.01% 4044

Other funds holding TTNP

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Vanguard Group's TTNP Position: Q1 2024 in Review

Vanguard Group sold out of Titan Pharmaceuticals (TTNP) in Q1 2024, closing a stake of 4,103 shares — an estimated $33.8K sold.

Vanguard Group first reported a position in TTNP in Q4 2015 and held it in 33 quarters. The position peaked at $3.69M in Q3 2016. 17 funds tracked by Wall St. Rank hold TTNP as of Q1 2024.

  • Vanguard Group reported no remaining Titan Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 4,103 Titan Pharmaceuticals shares in Q1 2024, an estimated $33.8K.
  • Vanguard Group first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 33 quarters.
  • Vanguard Group's Titan Pharmaceuticals position peaked at $3.69M in Q3 2016.
  • 17 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.